TNSN98229A1 - Formulation pharmaceutique orale a liberation prolongee - Google Patents

Formulation pharmaceutique orale a liberation prolongee

Info

Publication number
TNSN98229A1
TNSN98229A1 TNTNSN98229A TNSN98229A TNSN98229A1 TN SN98229 A1 TNSN98229 A1 TN SN98229A1 TN TNSN98229 A TNTNSN98229 A TN TNSN98229A TN SN98229 A TNSN98229 A TN SN98229A TN SN98229 A1 TNSN98229 A1 TN SN98229A1
Authority
TN
Tunisia
Prior art keywords
extended release
pharmaceutical formulation
oral pharmaceutical
release oral
pase
Prior art date
Application number
TNTNSN98229A
Other languages
English (en)
Inventor
Lundberg Per-Johan
Karehill Per-Gunnar
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Publication of TNSN98229A1 publication Critical patent/TNSN98229A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

UNE FORMULATION PHARMACEUTIQUE A LIBERATION PROLONGEE ET A ENROBAGE ENTERIQUE D'UN INHIBITEUR DE H+ - K+ - AT Pase DONNANT UNE CONCENTRATION PROLONGEE D'UN INHIBITEUR DE H+ - K+ - AT Pase DANS LE PLASMA. LA PRESENCE PROLONGEE DANS LE PLASMA EST OBTENUE PAR UNE COMPOSITION PHARMACEUTIQUE QUI COMPREND UNE SUBTANCE CENTRALE COMPOSEE D'UNE MATRICE HYDROPHILE OU HYDROPHOBE, DE L'INHIBITEUR DE H+ - K+ - AT Pase ET FACULTATIVEMENT DES EXCIPIENTS PHARMACEUTIQUEMENT ACCEPTABLES. LA FORMULATION PEUT ETRE ADMINISTREE UNE FOIS PAR JOUR.
TNTNSN98229A 1997-12-22 1998-12-16 Formulation pharmaceutique orale a liberation prolongee TNSN98229A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II

Publications (1)

Publication Number Publication Date
TNSN98229A1 true TNSN98229A1 (fr) 2005-03-15

Family

ID=20409571

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98229A TNSN98229A1 (fr) 1997-12-22 1998-12-16 Formulation pharmaceutique orale a liberation prolongee

Country Status (39)

Country Link
US (1) US6605303B1 (fr)
EP (1) EP1043976B1 (fr)
JP (1) JP4865945B2 (fr)
KR (2) KR100755154B1 (fr)
CN (1) CN1171582C (fr)
AR (1) AR017201A1 (fr)
AT (1) ATE312602T1 (fr)
AU (1) AU759634B2 (fr)
BG (1) BG65028B1 (fr)
BR (1) BR9814378A (fr)
CA (1) CA2315261C (fr)
CY (1) CY1106072T1 (fr)
CZ (1) CZ299228B6 (fr)
DE (1) DE69832816T2 (fr)
DK (1) DK1043976T3 (fr)
DZ (1) DZ2685A1 (fr)
EE (1) EE04901B1 (fr)
ES (1) ES2252875T3 (fr)
HK (1) HK1034455A1 (fr)
HR (1) HRP20000380B1 (fr)
HU (1) HUP0101437A3 (fr)
IL (2) IL136827A0 (fr)
IS (1) IS5524A (fr)
MA (1) MA26576A1 (fr)
MY (1) MY126555A (fr)
NO (1) NO20003218L (fr)
NZ (1) NZ505127A (fr)
PL (1) PL193776B1 (fr)
RU (1) RU2214232C2 (fr)
SA (1) SA99191077B1 (fr)
SE (1) SE9704869D0 (fr)
SK (1) SK284988B6 (fr)
TN (1) TNSN98229A1 (fr)
TR (1) TR200001981T2 (fr)
TW (1) TWI249410B (fr)
UA (1) UA69397C2 (fr)
WO (1) WO1999032091A1 (fr)
YU (1) YU36700A (fr)
ZA (1) ZA9811239B (fr)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ318501A (en) * 1995-09-21 1999-06-29 Pharma Pass Llc Novel composition containing an acid-labile omeprazole and process for its preparation
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
WO1999029299A1 (fr) 1997-12-08 1999-06-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Nouvelle forme de suppositoire renfermant un compose actif acidolabile
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
WO2002032427A1 (fr) * 2000-10-20 2002-04-25 Galephar M/F Formulation stable administrable par voie orale contenant un derive de benzimidazole
PT1341528E (pt) * 2000-12-07 2012-03-20 Nycomed Gmbh Comprimido de desintegração rápida compreendendo um ingrediente activo lábil a ácido
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
MXPA04009968A (es) 2002-04-09 2004-12-13 Flamel Tech Sa Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
EP1815868A3 (fr) * 2002-09-26 2007-08-15 Astellas Pharma Inc. Agent améliorant l'absorption de médicaments
EP2596792A1 (fr) 2002-10-16 2013-05-29 Takeda Pharmaceutical Company Limited Préparations solides stables
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
US8980322B2 (en) 2003-03-17 2015-03-17 Takeda Pharmaceutical Company Limited Controlled release composition
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2005012289A1 (fr) * 2003-07-17 2005-02-10 Altana Pharma Ag Nouveau sel de (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (fr) * 2004-06-01 2005-12-01 Pharmascience Inc. Forme pharmaceutique mixte a l'etat sec contenant des derives de benzimidazole
EP1768668A2 (fr) * 2004-06-16 2007-04-04 Tap Pharmaceutical Products, Inc. Forme posologique a doses ppi multiples
US20090124702A1 (en) * 2005-01-25 2009-05-14 Pechetti Siva Satya Krishna Babu Pharmaceutical Compositions of Metformin
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
CN101389316A (zh) * 2005-12-28 2009-03-18 武田药品工业株式会社 控制释放固体制剂
WO2007138606A2 (fr) * 2006-06-01 2007-12-06 Dexcel Pharma Technologies Ltd. Formulation pharmaceutique comprenant des unités multiples
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2008112388A1 (fr) 2007-03-14 2008-09-18 Drugtech Corporation Agencement spatial de particules dans un dispositif servant a boire, pour l'administration orale d'agents pharmaceutiques
KR20170097787A (ko) * 2007-10-12 2017-08-28 다케다 파마슈티칼스 유에스에이, 인코포레이티드 음식 섭취와 관계없이 위장 장애를 치료하는 방법
US12011423B2 (en) 2007-11-06 2024-06-18 Foraviset Ltd. S-alkylisothiouronium derivatives for treating uterine hypercontractility disorders
EP2405898A2 (fr) 2009-03-09 2012-01-18 Council Of Scientific & Industrial Research Composition à libération lente d'un agent thérapeutique
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
DK2956149T3 (da) * 2013-02-13 2019-09-09 Redhill Biopharma Ltd Farmaceutiske sammensætninger til behandling af helicobacter pylori
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
EP3288556A4 (fr) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Compositions à désintégration par voie orale
WO2017145146A1 (fr) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprenant des inhibiteurs de la pompe à protons
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US5229181A (en) * 1990-10-30 1993-07-20 Amber Technologies Tubular knit cleanroom wiper
TW209174B (fr) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
ES2179829T3 (es) * 1992-09-18 2003-02-01 Yamanouchi Pharma Co Ltd Preparacion de hidrogel de liberacion prolongada.
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07330629A (ja) * 1994-06-02 1995-12-19 Nippon Shokubai Co Ltd 徐放性製剤
MX9600857A (es) * 1994-07-08 1997-06-28 Astra Ab Forma de dosificacion i en tabletas, con unidades multiples.
HUT78132A (hu) * 1994-07-08 2000-06-28 Astra Aktiebolag Omeprazol magnéziumsóját tartalmazó új orális gyógyszerforma
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US5945124A (en) 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
WO1997047285A1 (fr) * 1996-06-10 1997-12-18 Depomed, Inc. Systeme a caracteristiques de retention renforcees pour l'administration controlee par voie orale de medicaments a retention gastrique
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US7016717B2 (en) * 2002-07-05 2006-03-21 The Regents Of The University Of California Near-infrared spectroscopic tissue imaging for medical applications
ITPD20050230A1 (it) * 2005-07-28 2007-01-29 Marcato Spa Macchina ad uso domestico per la estrusione di paste alimentari fresche

Also Published As

Publication number Publication date
DE69832816D1 (de) 2006-01-19
KR20010033428A (ko) 2001-04-25
JP4865945B2 (ja) 2012-02-01
DZ2685A1 (fr) 2003-03-29
HRP20000380B1 (en) 2007-08-31
CZ299228B6 (cs) 2008-05-21
CA2315261C (fr) 2008-02-12
SK8072000A3 (en) 2001-01-18
EP1043976B1 (fr) 2005-12-14
EP1043976A1 (fr) 2000-10-18
ES2252875T3 (es) 2006-05-16
WO1999032091A1 (fr) 1999-07-01
IS5524A (is) 2000-06-08
JP2001526211A (ja) 2001-12-18
EE04901B1 (et) 2007-10-15
SE9704869D0 (sv) 1997-12-22
NO20003218D0 (no) 2000-06-21
SK284988B6 (sk) 2006-04-06
KR20060097069A (ko) 2006-09-13
BG104620A (en) 2001-04-30
HK1034455A1 (en) 2001-10-26
ZA9811239B (en) 1999-06-22
TR200001981T2 (tr) 2000-11-21
AU1991299A (en) 1999-07-12
DE69832816T2 (de) 2006-08-31
RU2214232C2 (ru) 2003-10-20
NO20003218L (no) 2000-08-22
PL341428A1 (en) 2001-04-09
UA69397C2 (uk) 2004-09-15
CZ20002314A3 (cs) 2000-11-15
AR017201A1 (es) 2001-08-22
ATE312602T1 (de) 2005-12-15
CY1106072T1 (el) 2011-06-08
KR100755154B1 (ko) 2007-09-04
EE200000383A (et) 2001-12-17
CA2315261A1 (fr) 1999-07-01
CN1171582C (zh) 2004-10-20
CN1284866A (zh) 2001-02-21
HRP20000380A2 (en) 2001-06-30
DK1043976T3 (da) 2006-03-20
BG65028B1 (bg) 2006-12-29
IL136827A (en) 2007-05-15
MA26576A1 (fr) 2004-12-20
MY126555A (en) 2006-10-31
IL136827A0 (en) 2001-06-14
PL193776B1 (pl) 2007-03-30
HUP0101437A3 (en) 2003-01-28
NZ505127A (en) 2003-02-28
SA99191077B1 (ar) 2006-07-11
US6605303B1 (en) 2003-08-12
BR9814378A (pt) 2000-10-10
YU36700A (sh) 2003-01-31
HUP0101437A2 (hu) 2001-10-28
AU759634B2 (en) 2003-04-17
TWI249410B (en) 2006-02-21

Similar Documents

Publication Publication Date Title
TNSN98229A1 (fr) Formulation pharmaceutique orale a liberation prolongee
FR2752732B1 (fr) Forme galenique a liberation prolongee de milnacipran
ATE226815T1 (de) Herstellung von arzneimitteln
DE69331948T2 (de) Angenehm schmeckende pharmazeutische zusammensetzungen
CA2301017A1 (fr) Utilisation de gallate de propyle pour augmenter la biodisponibilite de produits pharmaceutiques administres par voie orale
DE69520768T2 (de) Pharmazeutische Zubereitungen, die Fluoxetin enthalten
IE881916L (en) Press-coated dihydropyridine tablets
DE69100991D1 (de) Pharmazeutische formulierungen.
DE69940674D1 (de) Orale verabreichung von adenosin analogen
ATE267798T1 (de) Kombinierte wirkstoffe als methode zur gezielten wirkstoff-freisetzung
DK1028707T3 (da) Oftalmiske præparater med forlænget frigivelse og indeholdende vandopløselige medikamenter
TR199801180T2 (xx) Aneljestik etkiye sahip yeni bile�ikler.
CA2289717A1 (fr) Nouveau traitement de la constipation
DE3685392D1 (de) Galenische formen mit verzoegerter verapamil-freisetzung, deren herstellung und diese enthaltende arzneimittel.
ATE198152T1 (de) Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe
AU9159098A (en) Use of erythropoietin and iron preparations for the production of pharmaceutical combination preparations for the treatment of rheumatic diseases
CY1108863T1 (el) Φαρμακευτικο σκευασμα εκτεταμενης απελευθερωσης ανεξαρτητης απο το ρη
CA2231176A1 (fr) Composition pour administration rectale a action de longue duree
FR2598320B1 (fr) Compositions pharmaceutiques hydrosolubles contenant de l'ubiquinone en tant que principe actif, utiles dans differentes applications therapeutiques
BE1002182A5 (fr) Compositions pharmaceutiques.
ATE226065T1 (de) Feste instant-release-darreichungsformen und verfahren zu ihrer herstellung
ES2145517T3 (es) Nuevos derivados monofuncionalizados de edta, dtpa y ttha y su utilizacion en el diagnostico y en la terapia medicinales.
ITTO950554A0 (it) Diamidi aromatiche acide ad attivita' antigastrinica, procedimento perla loro preparazione e loro uso farmaceutico
BE1002256A3 (fr) Medicaments.
DK0927031T3 (da) Farmaceutisk sammensætning indeholdende nimesulid til oral admnistration